Clinical Trial Update: Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease [Phase 3]

View source ↗

Summary

Phase 3 study of fasiglifam (TAK-875) in adults with type 2 diabetes and cardiovascular disease or risk factors was terminated; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• TAK-875 (fasiglifam)

Snippet

Sponsor: Takeda | Conditions: Type 2 Diabetes, Cardiovascular Disease | Phase 3 | Status: TERMINATED | Results posted: 2015-08-21